Möchten Sie immer auf dem neuesten Stand bleiben?

It was an honor to attend the keynote address of Dr. Izpisúa whose scientific interests and vision for the future of humanity are world renowned

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for...

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile

We are pleased with advancements made with our R&D programs and... our lead asset PRP which we are preparing for our world-first, Phase 1b, clinical study